| Literature DB >> 35804841 |
Magdalena Ciążyńska1,2, Marta Pabianek1, Martyna Sławińska3, Adam Reich4, Bogumił Lewandowski5, Katarzyna Szczepaniak1, Małgorzata Ułańska1, Dariusz Nejc6, Robert Brodowski5, Michał Sobjanek3, Witold Owczarek7, Grażyna Kamińska-Winciorek8, Dariusz Lange9, Monika Słowińska7, Katarzyna Wróbel7, Andrzej Bieniek10, Anna Woźniacka11, Anika Pękala1, Łukasz Kuncman12, Magdalena Salińska11, Marcin Noweta2, Małgorzata Skibińska2, Joanna Narbutt2, Karol Ciążyński13, Marta Lewandowska14, Elżbieta Dziankowska-Zaborszczyk15, Aleksandra Lesiak2.
Abstract
BACKGROUND: Patients with diagnosed keratinocyte carcinomas (KCs) have an increased risk of subsequent skin cancers development. Current studies indicate that patients with subsequent tumors should be followed up regularly. However, none of the studies indicate the connection between the specific subtypes and an increased risk for further KCs development. The study assesses the differences in the risk of developing a subsequent skin cancer after a previous diagnosis of KC, especially considering individual types of skin malignances, and identifies potential factors associated with an increased risk of new cutaneous tumor describing non-invasive diagnosis and monitoring.Entities:
Keywords: basal cell carcinoma; keratinocyte carcinomas; non-invasive diagnosis and monitoring; non-melanoma skin cancer; squamous cell carcinoma
Year: 2022 PMID: 35804841 PMCID: PMC9264931 DOI: 10.3390/cancers14133069
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Clinical variables of patients with single and multiple KC.
| Single KC | Multiple KC | ||||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
| |||||
| Male | 3581 | 45.99% | 1224 | 53.22% | |
| Female | 4205 | 54.01% | 1076 | 46.78% | |
|
| |||||
| Mean | 70.16 | 71.17 | |||
| Min | 20 | 29 | |||
| Max | 102 | 87 | |||
|
| |||||
| Face | 5624 | 77.97% | 1613 | 74.33% | |
| Trunk | 827 | 11.47% | 292 | 13.46% | |
| Upper limb | 210 | 2.91% | 79 | 3.64% | |
| Lower limb | 274 | 3.80% | 82 | 3.78% | |
| Scalp | 111 | 1.54% | 49 | 2.26% | |
| Neck | 167 | 2.32% | 55 | 2.53% | |
| Unknown | 573 | 130 | |||
|
| |||||
| SCC | 1168 | 15.00% | 385 | 16.74% | |
| BCC | 6618 | 85.00% | 1915 | 83.26% | |
| Nodular | 1891 | 51.74% | 554 | 39.12% | |
| Superficial | 1159 | 31.71% | 456 | 32.20% | |
| Infiltrative | 489 | 13.38% | 333 | 23.52% | |
| Basosquamous | 116 | 3.17% | 73 | 5.16% | |
| Unknown BCC subtype | 2963 | 499 | |||
Results of the univariable and multivariable Cox proportional hazard regression analyses of all subsequent KC survival. HR, hazard ratio; 95% CI, 95% confidence interval.
| Univariate and Multivariable Analysis: | |
|---|---|
| Male gender a | 1.37 (1.25–1.51); |
| Diagnosis of a BCC b | 0.88 (0.77–1.01); |
| Diagnosis of a high-risk BCC c | 2.01 (1.73–2.34); |
| History of KC development d | 1.91 (1.63–2.21); |
| Age e | 0.93 (0.87–9.98); |
| Size of primary lesion e | 1.06 (1.01–1.11); |
a Female gender was defined as reference category. b Diagnosis of a SCC was a reference category. c Diagnosis of a low-risk BCC was a reference category. d Lack of subsequent skin neoplasm was defined as a reference category. e Univariate analysis.
Location of non-melanoma skin cancers.
| Site of First Primary KC | Site of Second Primary KC | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Face | Trunk | Upper Limb | Lower Limb | Scalp | Neck | Unknown | Total | ||||||||
| Face | 1372 | 85.1% | 75 | 4.6% | 23 | 1.4% | 22 | 1.4% | 16 | 1.0% | 32 | 2.0% | 73 | 4.5% | 1613 |
| Trunk | 111 | 38.0% | 115 | 39.4% | 26 | 8.9% | 14 | 4.8% | 6 | 2.1% | 5 | 1.7% | 15 | 5.1% | 292 |
| Upper limb | 23 | 29.1% | 13 | 16.5% | 30 | 38.0% | 4 | 5.1% | 1 | 1.3% | 4 | 5.1% | 4 | 5.1% | 79 |
| Lower limb | 24 | 29.3% | 8 | 9.8% | 7 | 8.5% | 40 | 48.8% | 0 | 0.0% | 0 | 0.0% | 3 | 3.7% | 82 |
| Scalp | 21 | 42.9% | 4 | 8.2% | 1 | 2.0% | 3 | 6.1% | 16 | 32.7% | 3 | 6.1% | 1 | 2.0% | 49 |
| Neck | 22 | 40.0% | 7 | 12.7% | 0 | 0.0% | 2 | 3.6% | 1 | 1.8% | 22 | 40.0% | 1 | 1.8% | 55 |
| Unknown | 67 | 51.5% | 23 | 17.7% | 4 | 3.1% | 5 | 3.8% | 1 | 0.8% | 4 | 3.1% | 26 | 20.0% | 130 |
| Total | 1640 | 245 | 91 | 90 | 41 | 70 | 123 | 2300 | |||||||
Data is marked with grey background when the second lesion occurred in the same location as the first one.
Type of non-melanoma skin cancers.
| Type of First Primary KC | Type of Second Primary KC | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCC | BCC | BCC Subtype | Total | ||||||||||||||
| Nodular | Superficial | Infiltrative | Basosquamous | Unknown BCC | Total BCC | ||||||||||||
|
|
| 62.3% | 134 | 37.7% | 17 | 4.8% | 5 | 1.4% | 3 | 0.8% | 0 | 0.0% | 109 | 30.7% | 355 | ||
|
| 243 | 12.5% | 1702 | 87.5% | 567 | 29.2% | 643 | 33.1% | 323 | 16.6% | 66 | 3.4% | 103 | 5.3% | 1945 | ||
|
| Nodular | 71 | 12.7% | 488 | 87.3% | 289 | 51.7% | 96 | 17.2% | 12 | 2.1% | 7 | 1.3% | 84 | 15.0% | 559 | |
| Superficial | 69 | 11.4% | 535 | 88.6% | 74 | 12.3% | 427 | 70.7% | 16 | 2.6% | 15 | 2.5% | 3 | 0.5% | 604 | ||
| Infiltrative | 18 | 5.5% | 312 | 94.5% | 86 | 26.1% | 62 | 18.8% | 155 | 47.0% | 5 | 1.5% | 4 | 1.2% | 330 | ||
| Basosquamous | 6 | 8.1% | 68 | 91.9% | 6 | 8.1% | 14 | 18.9% | 17 | 23.0% | 31 | 41.9% | 0 | 0.0% | 74 | ||
| unknown BCC | 79 | 20.9% | 299 | 79.1% | 112 | 29.6% | 44 | 11.6% | 123 | 32.5% | 8 | 2.1% | 12 | 3.2% | 378 | ||
|
| 464 | 1836 | 2300 | ||||||||||||||
Data is marked with grey background when the second lesion subtype is the same as the first one.
Pathological characteristics of multiple KC.
| First | Second | Third | Fourth | Fifth | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2300 | 2300 | 736 | 347 | 182 | ||||||
| Location of primary KC | ||||||||||
| Face | 1613 | 74.3% | 1640 | 75.3% | 531 | 72.1% | 236 | 68.0% | 132 | 72.5% |
| Trunk | 292 | 13.5% | 245 | 11.3% | 93 | 12.6% | 52 | 15.0% | 24 | 13.2% |
| Upper limb | 79 | 3.6% | 91 | 4.2% | 41 | 5.6% | 23 | 6.6% | 11 | 6.0% |
| Lower limb | 82 | 3.8% | 90 | 4.1% | 29 | 3.9% | 13 | 3.7% | 2 | 1.1% |
| Scalp | 49 | 2.3% | 41 | 1.9% | 18 | 2.4% | 10 | 2.9% | 3 | 1.6% |
| Neck | 55 | 2.5% | 70 | 3.2% | 25 | 3.4% | 13 | 3.7% | 10 | 5.5% |
| Unknown | 130 | 123 | 0 | 0 | 0 | |||||
| Size of primary KC [diameter, mm] | ||||||||||
| <5 | 104 | 4.8% | 221 | 9.9% | 85 | 11.5% | 51 | 14.7% | 36 | 19.8% |
| 5–10 | 654 | 30.0% | 667 | 30.0% | 287 | 39.0% | 153 | 44.1% | 82 | 45.1% |
| 10–20 | 846 | 38.8% | 832 | 37.4% | 246 | 33.4% | 122 | 35.2% | 56 | 30.8% |
| 20–50 | 487 | 22.3% | 419 | 18.8% | 101 | 13.7% | 20 | 5.8% | 8 | 4.4% |
| >50 | 89 | 4.1% | 85 | 3.8% | 15 | 2.0% | 0 | 0.0% | 0 | 0.0% |
| unknown | 120 | 76 | 2 | 1 | 0 | |||||
Figure 1Size of subsequent primary KC.
Figure 2Timing between subsequent primary KC development.
Figure 3Recommendation for follow up depending on skin cancer. * follow up: full body dermatology exam and dermatoscopy. ** the crucial prevention marked in bold.